Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model.

Front Oncol · 2019 · PMC6524318 · PMID 31134152

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

As expected, the control animals had the greatest tumor burden followed by the oral Talazoparib and NanoTalazoparib-treated groups, respectively, though the difference did not reach statistical significance ( Figures 3B,C ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.